Peptide Blocking CTLA-4 and B7-1 Interaction; Molecules; Vol. 26, iss. 2

Bibliografiske detaljer
Parent link:Molecules
Vol. 26, iss. 2.— 2021.— [252, 7 p.]
Institution som forfatter: Национальный исследовательский Томский политехнический университет Инженерная школа новых производственных технологий Научно-образовательный центр Н. М. Кижнера
Andre forfattere: Podlesnykh S. V. Stepan Vasiljevich, Abramova K. E. Kristina Evgenjevna, Gordeeva A. Anastasiya, Khlebnikov A. I. Andrey Ivanovich, Chapoval A. I. Andrey Ivanovich
Summary:Title screen
Discovery of the B7 family immune checkpoints such as CTLA-4 (CD152), PD-1 (CD279), as well as their ligands B7-1 (CD80), B7-2 (CD86), B7-H1 (PD-L1, CD274), and B7-DC (PD-L2, CD273), has opened new possibilities for cancer immunotherapy using monoclonal antibodies (mAb). The blockade of inhibitory receptors (CTLA-4 and PD-1) with specific mAb results in the activation of cancer patients’ T lymphocytes and tumor rejection. However, the use of mAb in clinics has several limitations including side effects and cost of treatment. The development of new low-molecular compounds that block immune checkpoints’ functional activity can help to overcome some of these limitations. In this paper, we describe a synthetic peptide (p344) containing 14 amino acids that specifically interact with CTLA-4 protein. A 3D computer model suggests that this peptide binds to the 99MYPPPY104 loop of CTLA-4 protein and potentially blocks the contact of CTLA-4 receptor with B7-1 ligand. Experimental data confirm the peptide-specific interaction with CTLA-4 and its ability to partially block CTLA-4/B7-1 binding. The identified synthetic peptide can be used for the development of novel immune checkpoint inhibitors that can block CTLA-4 functional activity for cancer immunotherapy.
Sprog:engelsk
Udgivet: 2021
Fag:
Online adgang:https://doi.org/10.3390/molecules26020253
Format: Electronisk Book Chapter
KOHA link:https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=664433

MARC

LEADER 00000naa0a2200000 4500
001 664433
005 20250415160918.0
035 |a (RuTPU)RU\TPU\network\35617 
035 |a RU\TPU\network\35426 
090 |a 664433 
100 |a 20210413d2021 k||y0rusy50 ba 
101 0 |a eng 
102 |a CH 
135 |a drcn ---uucaa 
181 0 |a i  
182 0 |a b 
200 1 |a Peptide Blocking CTLA-4 and B7-1 Interaction  |f S. V. Podlesnykh, K. E. Abramova, A. Gordeeva [et al.] 
203 |a Text  |c electronic 
300 |a Title screen 
320 |a [References: 20 tit.] 
330 |a Discovery of the B7 family immune checkpoints such as CTLA-4 (CD152), PD-1 (CD279), as well as their ligands B7-1 (CD80), B7-2 (CD86), B7-H1 (PD-L1, CD274), and B7-DC (PD-L2, CD273), has opened new possibilities for cancer immunotherapy using monoclonal antibodies (mAb). The blockade of inhibitory receptors (CTLA-4 and PD-1) with specific mAb results in the activation of cancer patients’ T lymphocytes and tumor rejection. However, the use of mAb in clinics has several limitations including side effects and cost of treatment. The development of new low-molecular compounds that block immune checkpoints’ functional activity can help to overcome some of these limitations. In this paper, we describe a synthetic peptide (p344) containing 14 amino acids that specifically interact with CTLA-4 protein. A 3D computer model suggests that this peptide binds to the 99MYPPPY104 loop of CTLA-4 protein and potentially blocks the contact of CTLA-4 receptor with B7-1 ligand. Experimental data confirm the peptide-specific interaction with CTLA-4 and its ability to partially block CTLA-4/B7-1 binding. The identified synthetic peptide can be used for the development of novel immune checkpoint inhibitors that can block CTLA-4 functional activity for cancer immunotherapy. 
461 |t Molecules 
463 |t Vol. 26, iss. 2  |v [252, 7 p.]  |d 2021 
610 1 |a труды учёных ТПУ 
610 1 |a электронный ресурс 
610 1 |a peptides 
610 1 |a immune checkpoints 
610 1 |a peptide microarray 
610 1 |a cancer 
610 1 |a immunotherapy 
610 1 |a пептиды 
610 1 |a микрочипы 
610 1 |a иммунотерапия 
610 1 |a рак 
701 1 |a Podlesnykh  |b S. V.  |g Stepan Vasiljevich 
701 1 |a Abramova  |b K. E.  |g Kristina Evgenjevna 
701 1 |a Gordeeva  |b A.  |g Anastasiya 
701 1 |a Khlebnikov  |b A. I.  |c Chemist  |c Professor of Tomsk Polytechnic University  |f 1963-  |g Andrey Ivanovich  |3 (RuTPU)RU\TPU\pers\33927  |9 17500 
701 1 |a Chapoval  |b A. I.  |g Andrey Ivanovich 
712 0 2 |a Национальный исследовательский Томский политехнический университет  |b Инженерная школа новых производственных технологий  |b Научно-образовательный центр Н. М. Кижнера  |3 (RuTPU)RU\TPU\col\23556 
801 2 |a RU  |b 63413507  |c 20210413  |g RCR 
850 |a 63413507 
856 4 0 |u https://doi.org/10.3390/molecules26020253 
942 |c CF